Hetero Labs Gets CDSCO Panel Nod to Study Tedizolid Phosphate for Acute Bacterial Skin and Skin Structure Infections

Tedizolid phosphate is an oxazolidinone class antibiotic that inhibits bacterial protein synthesis and is proven to be effective in the treatment of certain Gram-positive bacterial infections.

Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid, and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid

At the recent SEC meeting for antimicrobials and antivirals held on July 25, 2024, the expert panel reviewed the proposal for the grant of permission to conduct the Phase III clinical trial study for the new drug Tedizolid Phosphate 200 mg tablet and Tedizolid Phosphate for injection 200 mg/vial for treatment of adult patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

After detailed deliberation, the committee recommended the grant of permission to conduct a phase III clinical study as per protocol presented by the firm.

Also Read: Pfizer gets CDSCO Panel nod to study Somatrogon